Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Regeneron’s third-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea’s sales. Eylea continues to perform well. Dupixent launch in the United States for moderate-to-severe atopic dermatitis is progressing well. The drug was also approved in Europe. The geographic expansion of the drug will further boost sales. Moreover, the company is also looking to expand Dupixent’s label in uncontrolled asthma. The approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line and reduce the company’s dependence on Eylea for growth. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. Shares have outperformed the industry so far in 2017. However, sales of Praluent have failed to impress payer utilization management restrictions in the United States.”

A number of other equities research analysts also recently issued reports on the stock. J P Morgan Chase & Co reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 31st. Barclays PLC downgraded shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $450.00 to $395.00 in a research report on Friday, October 20th. Guggenheim reissued a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Morgan Stanley reissued an “equal weight” rating and set a $490.00 price objective (up from $450.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, October 6th. Finally, BMO Capital Markets reissued a “market perform” rating and set a $484.00 price objective (up from $421.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $481.49.

Regeneron Pharmaceuticals (NASDAQ REGN) traded down $10.92 during mid-day trading on Tuesday, hitting $393.62. 1,417,500 shares of the stock were exchanged, compared to its average volume of 902,722. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The firm has a market cap of $43,346.87, a P/E ratio of 35.03, a price-to-earnings-growth ratio of 1.56 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. During the same period last year, the firm earned $3.13 EPS. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. equities research analysts expect that Regeneron Pharmaceuticals will post 13.77 earnings per share for the current year.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/14/regeneron-pharmaceuticals-inc-regn-stock-rating-upgraded-by-zacks-investment-research.html.

In other Regeneron Pharmaceuticals news, SVP Robert E. Landry sold 427 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $493.43, for a total value of $210,694.61. Following the transaction, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,489,719.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 88,942 shares of company stock worth $42,064,076 in the last 90 days. Company insiders own 10.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Alpha Windward LLC lifted its holdings in Regeneron Pharmaceuticals by 0.3% in the 2nd quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 1 shares in the last quarter. Regentatlantic Capital LLC lifted its holdings in Regeneron Pharmaceuticals by 0.9% in the 2nd quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock worth $264,000 after buying an additional 5 shares in the last quarter. Capital Planning Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 2.1% in the 2nd quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 12 shares in the last quarter. Sequoia Financial Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 1.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 12 shares in the last quarter. Finally, Princeton Capital Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.6% in the 2nd quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock worth $1,233,000 after buying an additional 15 shares in the last quarter. Hedge funds and other institutional investors own 67.80% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.